16,175,000 Shares in Haleon PLC Sponsored ADR $HLN Purchased by Norges Bank

Norges Bank purchased a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,175,000 shares of the company’s stock, valued at approximately $163,529,000. Norges Bank owned about 0.36% of Haleon as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Atlantic Union Bankshares Corp boosted its holdings in Haleon by 293.7% during the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after purchasing an additional 2,758 shares during the last quarter. Stance Capital LLC purchased a new position in Haleon during the third quarter worth about $34,000. Geneos Wealth Management Inc. boosted its holdings in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the last quarter. Assetmark Inc. boosted its holdings in Haleon by 26.6% during the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after purchasing an additional 1,252 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Haleon by 428.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after purchasing an additional 5,124 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Performance

Shares of HLN stock opened at $8.72 on Thursday. The firm has a market cap of $38.61 billion, a price-to-earnings ratio of 22.35, a P/E/G ratio of 1.98 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28. The firm’s 50-day simple moving average is $9.45 and its two-hundred day simple moving average is $9.94.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion during the quarter. As a group, equities analysts forecast that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on HLN shares. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.